Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Sumitomo Chemical Co., Ltd.	2. Issuer Name and Ticker or Trading Symbol Myovant Sciences Ltd. [ MYOV ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    __X__ 10% Owner _____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle) 27-1, SHINKAWA 2-CHOME,	3. Date of Earliest Transaction (MM/DD/YYYY) 4/23/2020
(Street) CHUO-KU, TOKYO, M0 104-8260 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	4/23/2020		P		35000 (1)	A	$12.3458 (2)	47814104	I	See Footnote (3)
Common Stock	4/24/2020		P		43086 (4)	A	$12.1465 (2)	47857190	I	See Footnote (5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:
(1)	This acquisition of a total of 35,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan").
(2)	The price reported in column 4 is the average stock price.
(3)	Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,814,104 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.
(4)	This acquisition of a total of 43,086 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan.
(5)	Sumitovant directly owns 47,857,190 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Sumitomo Chemical Co., Ltd. 27-1, SHINKAWA 2-CHOME CHUO-KU, TOKYO, M0 104-8260		X
Dainippon Sumitomo Pharma Co Ltd 6-8 DOSHOMACHI 2-CHOME CHUO-KU, OSAKA, M0 541-0045		X
Sumitovant Biopharma Ltd. 11-12 ST. JAMES'S SQUARE SUITE 1 3RD FLOOR LONDON, X0 SW1Y 4LB		X

Signatures
Sumitomo Chemical Co., Ltd., By: /s/ Krunal Shah, as Attorney-in-Fact		4/27/2020
**Signature of Reporting Person		Date
Sumitomo Dainippon Pharma Co., Ltd., By: Tsutomu Nakagawa, Senior Director, Global Corporate Strategy, /s/ Tsutomu Nakagawa		4/27/2020
**Signature of Reporting Person		Date
Sumitovant Biopharma Ltd., By: /s/ Krunal Shah, as Attorney-in-Fact		4/27/2020
**Signature of Reporting Person		Date